Gilead Sciences, Inc. (GILD) and LG Life Sciences, Ltd. Announce Global License Agreement to Advance Novel Drug Candidates for Treatment of Fibrotic Diseases  
11/7/2007 11:32:44 AM

FOSTER CITY, Calif. & SEOUL, South Korea--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) and LG Life Sciences, Ltd. (LGLS) today announced that the companies have entered into an exclusive license agreement focused on the development of caspase inhibitors for the treatment of fibrotic diseases. The agreement grants Gilead commercialization rights to LGLS’ caspase inhibitors, including LB84451, LGLS’ lead compound. LB84451 is an investigational pan-caspase inhibitor currently being evaluated in a Phase IIa clinical trial in patients chronically infected with the hepatitis C virus.